QbD more likely in generics than brand drugs; World Courier expands trial supply network;

> Generics makers have a greater probability designing processes that follow the Quality by Design regimen and using continuous processes for their manufacturing versus brand companies. Article

> World Courier says it will expand its GMP-compliant clinical trial supply chain services network to 13 strategic and emerging markets; among them is Singapore, now home to a 135,000-square-foot distribution facility. World Courier release

> Indian pharma Shilpa Medicare said it has received European Union GMP approval from Germany for two of its manufacturing sites for production of cancer drugs. Item

> Visible particle contamination has driven Lundbeck to a voluntary recall of two lots of NeoProfen (ibuprofen lysine) injection. Lundbeck release

> U.K. contract manufacturer and fill/finish specialist SCM Pharma has launched two services: sterility testing, and bacterial endotoxin testing. SCM Pharma release

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.